|
Video: What is a Stock Split?
|
|
CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions. Co.'s primary focus is on the development of its primary product candidate, DefenCath, for potential commercialization in the U.S. and other main markets. Co. has in-licensed the worldwide rights to develop and commercialize DefenCath and Neutrolin®. DefenCath is an anti-infective solution intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition and oncology. According to our CorMedix stock split history records, CorMedix has had 1 split. | |
|
CorMedix (CRMD) has 1 split in our CorMedix stock split history database. The split for CRMD took place on March 26, 2019. This was a 1 for 5 reverse split, meaning for each 5 shares of CRMD owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split.
When a company such as CorMedix conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CorMedix stock split history from start to finish, an original position size of 1000 shares would have turned into 200 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into CorMedix shares, starting with a $10,000 purchase of CRMD, presented on a split-history-adjusted basis factoring in the complete CorMedix stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
04/17/2024 |
|
Start price/share: |
$9.45 |
|
End price/share: |
$5.44 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-42.43% |
|
Average Annual Total Return: |
-5.38% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,753.88 |
|
Years: |
9.99 |
|
|
|
Date |
Ratio |
03/26/2019 | 1 for 5 |
|
|